Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]".

	Organisation	Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Organisation 2	Sweden (govt)
	Product	ilixadencel
	Product 2	investment banking
	Index term	Immunicum–SEVERAL: investment, 201810– capital increase SEK351m with 40.3m new shares at SEK8.5/share
	Person	de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
	Person 2	Gertz, Michaela (Immunicum 201802– CFO before PledPharma AB + Accelerator Nordic AB + ITP Invest AB)

Original document
accessed by [iito] on 2018-10-16

Record changed: 2018-10-20

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

[1] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....
[2] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
[3] Immunicum AB. (9/27/18). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October"....
[4] Immunicum AB. (1/31/18). "Press Release: Michaela Gertz Joins Immunicum as CFO"....
[5] Immunicum AB. (1/15/18). "Press Release: Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm"....
[6] Immunicum AB. (12/29/17). "Press Release: Immunicum AB (publ) Announces the Outcome of the Rights Issue [Not for US, AU, CA, et al.]"....
[7] Immunicum AB. (8/22/17). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September"....
[8] Immunicum AB. (8/18/17). "Press Release: Interim Report Q2 – Corporate Update and Outlook"....
[9] Immunicum AB. (8/17/17). "Press Release: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel"....
[10] Immunicum AB. (5/19/17). "Press Release: Quarterly Report January-March 2017"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]